Close the acquisition of Acceleron Pharma
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Oct 2021
- Due
- 31 Dec 2021
- Delivered
- by 19 Nov 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The transaction is expected to close in the fourth quarter of 2021.”
What we found
Evidence strength A What the grades mean
Merck successfully completed the acquisition of Acceleron Pharma Inc. in November 2021, which falls within the fourth quarter of 2021.
-
A Merck & Co., Inc. 10-Q filed 2022-08-05
“Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron Pharma Inc.” ✓ confirmed on the page
-
A Merck & Co., Inc. 8-K filed 2022-02-03
“The company advanced its broad pipeline, closed the acquisition of Acceleron Pharma Inc. (Acceleron) and delivered initial shipments of molnupiravir” ✓ confirmed on the page
Market reaction: the shares moved -3.2% against the S&P 500 over the three sessions around the disclosure (2 Feb 2022 to 7 Feb 2022). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Acquisition of Acceleron Pharma
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: upon successful completion of the tender offer and receipt of necessary regulatory approvals
- Depends on
- Regulatory, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Merck & Co., Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MRK-004277 · Corrections policy